Pieris Announces Preclinical In Vitro And In Vivo Data For Its Anticalin(r) PRS-080 Hepcidin Antagonist Drug ProgramAnna Ohlden
dose of PRS-080-PEG30 in cynomolgus monkeys. Importantly, in these animals, suppression of free hepcidin and subsequent plasma iron elevation were sustained during repeated s.c. dosing. After repeated dosing and followed by a treatment-free interval, all iron parameters returned to pre-dose ...
Antagonistic Anticalin therapeutics have been developed for systemic administration (e.g., PRS-080: anti-hepcidin) or pulmonary delivery (e.g. PRS-060/AZD1402: anti-interleukin [IL]-4-Ra). Moreover, Anticalin proteins allow molecular formatting as bi- and even multispecific fusion proteins, ...